Table 1 Patient characteristics of responders and non-responders
Variable | Total n = 115 | Responders n = 34 | Non-responders n = 81 | p-value |
|---|---|---|---|---|
Sex | ||||
Female | 15 (13.0%) | 7 (20.6%) | 8 (9.9%) | 0.1196 |
Male | 100 (87.0%) | 27 (79.4%) | 73 (90.1%) | |
Age, years | ||||
Mean (SD) | 65.3 (8.7) | 66.1 (7.8) | 65.0 (9.1) | 0.5156 |
Median (IQR) | 65.0 (12.0) | 67.0 (13.0) | 65.0 (12.0) | |
Age category, years | ||||
≤ 65 | 55 (47.8%) | 15 (44.1%) | 40 (49.4%) | 0.606 |
> 65 | 60 (52.2%) | 19 (55.9%) | 41 (50.6%) | |
Ethnicity | ||||
Missing | 10 (8.7%) | 4 (11.8%) | 6 (7.4%) | 0.6638 |
Hispanic or Latin | 5 (4.8%) | 1 (3.3%) | 4 (5.3%) | |
Other | 100 (95.2%) | 29 (96.7%) | 71 (94.7%) | |
Race | ||||
Missing | 11 (9.6%) | 4 (11.8%) | 7 (8.6%) | 0.2326 |
Black | 2 (1.9%) | 0 | 2 (2.7%) | |
Other | 3 (2.9%) | 2 (6.7%) | 1 (1.4%) | |
White | 99 (95.2%) | 28 (93.3%) | 71 (95.9%) | |
ECOG status | ||||
0 | 90 (78.3%) | 27 (79.4%) | 63 (77.8%) | 0.8463 |
1 | 25 (21.7%) | 7 (20.6%) | 18 (22.2%) | |
HCC diagnosis by: | ||||
Missing | 2 (1.7%) | 1 (2.9%) | 1 (1.2%) | 0.7518 |
EASL criteria | 50 (43.5%) | 13 (38.2%) | 37 (45.7%) | |
Histology | 50 (43.5%) | 15 (44.1%) | 35 (43.2%) | |
Other | 13 (11.3%) | 5 (14.7%) | 8 (9.9%) | |
Hepatitis B | ||||
No | 104 (90.4%) | 31 (91.2%) | 73 (90.1%) | 0.8609 |
Yes | 11 (9.6%) | 3 (8.8%) | 8 (9.9%) | |
Hepatitis C | ||||
No | 81 (70.4%) | 26 (76.5%) | 55 (67.9%) | 0.3581 |
Yes | 34 (29.6%) | 8 (23.5%) | 26 (32.1%) | |
Alcohol etiology | ||||
No | 63 (54.8%) | 16 (47.1%) | 47 (58.0%) | 0.2809 |
Yes | 52 (45.2%) | 18 (52.9%) | 34 (42.0%) | |
Previous therapies | ||||
TACE | 28 (24.3%) | 9 (26.5%) | 19 (23.5%) | 0.7311 |
TAE | 2 (1.7%) | 0 | 2 (2.5%) | 0.3553 |
Resection | 21 (18.3%) | 9 (26.5%) | 12 (14.8%) | 0.1398 |
RFA | 12 (10.4%) | 6 (17.6%) | 6 (7.4%) | 0.1012 |
Brachytherapy | 5 (4.3%) | 1 (2.9%) | 4 (4.9%) | 0.6318 |
Max. diameter of largest lesion | ||||
Mean (SD) | 68.0 (59.6) | 69.8 (85.5) | 67.3 (44.6) | 0.2678 |
Median (IQR) | 57.0 (45.0) | 50.0 (40.0) | 59.5 (52.0) | |
Portal vein infiltration | ||||
Yes | 60 (52.2%) | 21 (61.8%) | 39 (48.1%) | 0.1822 |
Baseline metastasis | ||||
Yes | 6 (5.2%) | 0 | 6 (7.4%) | 0.1031 |
BCLC | ||||
B | 34 (29.6%) | 9 (26.5%) | 25 (30.9%) | 0.6375 |
C | 81 (70.4%) | 25 (73.5%) | 56 (69.1%) | |
Up-to-7 criterion | ||||
Inside | 17 (14.8%) | 7 (20.6%) | 10 (12.3%) | 0.2558 |
Outside | 98 (85.2%) | 27 (79.4%) | 71 (87.7%) | |
Total bilirubin (μmol/L) | ||||
Mean (SD) | 16.1 (7.1) | 15.4 (7.3) | 16.3 (7.1) | 0.4752 |
Median (IQR) | 14.9 (10.0) | 14.4 (9) | 15.0 (9.5) | |
Albumin g/L | ||||
Mean (SD) | 37.8 (8.3) | 38.9 (8.5) | 37.4 (8.2) | 0.3823 |
Median (IQR) | 39.0 (7.7) | 39.9 (6.5) | 39.0 (8.0) | |
ALBI score | ||||
Mean (SD) | −2.5 (0.7) | −2.6 (0.8) | −2.4 (0.7) | 0.2331 |
Median (IQR) | −2.5 (0.8) | −2.7 (0.7) | −2.5 (0.7) | |
Child-Pugh score | ||||
A | 105 (91.3%) | 33 (97.1%) | 72 (88.9%) | 0.1559 |
B | 10 (8.7%) | 1 (2.9%) | 9 (11.1% | |